Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...

Pfizer’s Gene Therapy Pullback Continues With Termination of Beqvez Bluebird Bio isn’t the only company with gene therapy commercialization challenges. Pfizer is discontinuing development and ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.